Zimmer Biomet (NYSE:ZBH) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?

Key Points

• Zimmer Biomet shares fell below their 50-day moving average, trading as low as $93.23 versus the $95.34 average, though the 200-day average remains lower at $91.27.
• Analyst sentiment is mostly neutral: 15 analysts rate the stock Hold, compared with six Buys and one Sell. The consensus price target is $103.33.
• The company recently exceeded quarterly earnings and revenue estimates, while maintaining fiscal 2026 EPS guidance of $8.47–$8.59. Zimmer Biomet also declared a quarterly dividend of $0.24 per share, representing a 1.0% yield.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $95.34 and traded as low as $93.23. Zimmer Biomet shares last traded at $94.5130, with a volume of 1,858,632 shares traded.

Analyst Upgrades and Downgrades

Several analysts recently commented on ZBH shares. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Wall Street Zen lowered shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Canaccord Genuity Group increased their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a research report on Monday, August 10th. Sanford C. Bernstein increased their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a research report on Thursday, August 6th. Finally, Barclays raised shares of Zimmer Biomet to a "hold" rating in a research note on Wednesday, October 7th. Six equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $103.33.

Zimmer Biomet Price Performance

The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The stock has a market capitalization of $18.03 billion, a price-to-earnings ratio of 23.00, a PEG ratio of 1.73 and a beta of 0.49. The stock's 50 day simple moving average is $95.34 and its 200-day simple moving average is $91.27.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet's dividend payout ratio is presently 23.36%.

Insider Activity

In other Zimmer Biomet news, insider Chad F. Phipps sold 3,000 shares of the business's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares of the company's stock, valued at $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the company's stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. OMERS ADMINISTRATION Corp bought a new stake in Zimmer Biomet during the 2nd quarter valued at approximately $922,000. Hsbc Holdings PLC acquired a new stake in Zimmer Biomet in the 2nd quarter valued at approximately $35,417,000. Legal & General Group Plc bought a new position in Zimmer Biomet in the 2nd quarter worth approximately $126,167,000. Rakuten Investment Management Inc. bought a new position in Zimmer Biomet in the 2nd quarter worth approximately $2,945,000. Finally, Munich Reinsurance Co Stock Corp in Munich bought a new position in Zimmer Biomet in the 2nd quarter worth approximately $3,753,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.

Its portfolio also includes orthopedic surgical equipment, robotic- and computer-assisted technologies, biologics and other solutions designed to support joint reconstruction, spine procedures and dental applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.